journal article·2019-12-04Open access

miR-342 suppresses the proliferation and invasion of acute myeloid leukemia by targeting Naa10p

Haiyan Wang, Heng He, Chunyan Yang

Abstract

Accumulating studies showed that microRNAs are maintaining a variety of important biological processes but the underlying mechanism in proliferation and tumourigenicity is unclear. In this study we show that miR-342 expression in bone marrow and patients' sera of childhood acute myeloid leukemia (AML) was both significantly higher than those in the corresponding normal controls. Functional assays demonstrated that forced expression of miR-342 significantly suppresses AML cell proliferation and G1/S transition of leukemia cells. Mechanistically, bioinformatics prediction and luciferase reporter assay identified N-a-acetyltransferase 10 protein (Naa10p) as a direct molecular target of miR-342, Naa10p siRNA significantly repressed cell proliferation and increased cell apoptosis. In conclusion, our study confirmed that miR-342/Naa10p plays key roles in AML progression, providing insights into underlying mechanisms of AML pathogenesis and also a potential therapeutic target for this malignancy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: MicroRNA in disease regulation · RNA Interference and Gene Delivery · Circular RNAs in diseases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Hematology, Affiliated Hospital of Jining Medical University

Department of Digestive Medicine, Affiliated Hospital of Jining Medical University

References (29)

Show source-provided references
1. 10.1016/j.ccr.2012.10.01710.1016/j.ccr.2012.10.017 ↗
2. 10.1182/blood-2011-10-38571610.1182/blood-2011-10-385716 ↗
3. 10.1038/aps.2016.12110.1038/aps.2016.121 ↗
4. 10.1016/j.dib.2016.07.03510.1016/j.dib.2016.07.035 ↗
5. 10.3892/ijo.2014.239010.3892/ijo.2014.2390 ↗
6. 10.3322/CA.2007.001010.3322/CA.2007.0010 ↗
7. 10.1016/j.leukres.2017.01.02810.1016/j.leukres.2017.01.028 ↗
8. 10.1038/bcj.2016.11010.1038/bcj.2016.110 ↗
9. 10.7754/Clin.Lab.2015.15060610.7754/Clin.Lab.2015.150606 ↗
10. 10.18632/oncotarget.1294710.18632/oncotarget.12947 ↗
11. Gao Y, Zhang SG, Wang ZH, et al. Down-regulation of miR-342-3p in hepatocellular carcinoma tissues and its prognostic significance. Euro Rev Med Pharmacol Sci. 2017;21:2098–2102.
12. 10.1016/j.febslet.2014.07.02010.1016/j.febslet.2014.07.020 ↗
13. 10.1016/j.bbrc.2014.12.11910.1016/j.bbrc.2014.12.119 ↗
14. Tai MC, Kajino T, Nakatochi M. et al. miR-342-3p regulates MYC transcriptional activity via direct repression of E2F1 in human lung cancer. Carcinogenesis. 2015;36:1464–1473.
15. 10.1158/0008-5472.CAN-06-317110.1158/0008-5472.CAN-06-3171 ↗
16. 10.1158/0008-5472.CAN-09-325810.1158/0008-5472.CAN-09-3258 ↗
17. 10.1038/sj.onc.120946910.1038/sj.onc.1209469 ↗
18. 10.1093/jnci/djq02610.1093/jnci/djq026 ↗
19. 10.1111/j.1365-2443.2008.01235.x10.1111/j.1365-2443.2008.01235.x ↗
20. 10.1126/scisignal.200059010.1126/scisignal.2000590 ↗
21. 10.1007/s13277-015-4563-z10.1007/s13277-015-4563-z ↗
22. 10.2174/15680090878624111310.2174/156800908786241113 ↗
23. 10.1093/carcin/bgu13210.1093/carcin/bgu132 ↗
24. 10.1007/s13277-015-3154-310.1007/s13277-015-3154-3 ↗
25. 10.3727/096504017X1488648541742610.3727/096504017X14886485417426 ↗
26. 10.3892/ol.2015.383110.3892/ol.2015.3831 ↗
27. 10.1371/journal.pone.008703910.1371/journal.pone.0087039 ↗
28. 10.1074/jbc.M115.71015210.1074/jbc.M115.710152 ↗
29. 10.3892/ijo.2016.348410.3892/ijo.2016.3484 ↗